De novo renal flares in SLE patients treated for active extra renal disease within five phase Ill clinical trials of belimumab. Implications for revisiting belimumab dose

被引：0

作者：

Parodis, I. ^{[1
,2
,3
]}

Lindblom, J. ^{[1
,2
]}

Cetrez, N. ^{[1
,2
]}

Palazzo, L. ^{[1
,2
]}

Ala, H. ^{[1
,2
]}

Houssiau, F. ^{[4
,5
]}

Sjowall, C. ^{[6
]}

Rovin, B. ^{[7
]}

机构：

[1] Karolinska Inst, Div Rheumatol, Dept Med Solna, Solna, Sweden

[2] Karolinska Univ Hosp, Solna, Sweden

[3] Orebro Univ, Fac Med & Hlth, Dept Rheumatol, Orebro, Sweden

[4] Catholic Univ Louvain, Pole Pathol Rhumatismales Inflammatoires & Syst, Inst Rech Expt & Clin, Louvain, Belgium

[5] Clin Univ St Luc, Serv Rhumatol, Louvain, Belgium

[6] Linkoping Univ, Dept Biomed & Clin Sci, Div Inflammat & Infect Rheumatol, Linkoping, Sweden

[7] Ohio State Univ, Coll Med, Dept Internal Med, Columbus, OH USA

来源：

关键词：

Systemic lupus erythematosus; lupus nephritis;

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

OP34

引用

页码：46 / 46

页数：1